PubRank

Jacob P Laubach

Author PubWeight™ 22.41‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med 2015 3.05
2 Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med 2015 2.04
3 Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies. Blood 2010 1.50
4 Kidney disease and multiple myeloma. Clin J Am Soc Nephrol 2013 1.26
5 Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol 2011 1.26
6 Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol 2011 1.20
7 Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood 2011 1.11
8 Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol 2009 1.00
9 Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res 2013 0.94
10 The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol 2012 0.91
11 Pathological crystallization of human immunoglobulins. Proc Natl Acad Sci U S A 2012 0.90
12 Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol 2012 0.89
13 The spectrum of kidney involvement in lymphoma: a case report and review of the literature. Am J Kidney Dis 2010 0.86
14 Phase transitions in human IgG solutions. J Chem Phys 2013 0.85
15 Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. J Natl Compr Canc Netw 2010 0.83
16 A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol 2011 0.83
17 The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. Future Oncol 2015 0.83
18 Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol 2014 0.82
19 Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Expert Rev Anticancer Ther 2015 0.82
20 Hematology: Thalidomide maintenance in multiple myeloma. Nat Rev Clin Oncol 2009 0.76
21 Having a heavy heart: approaches to infiltrative cardiomyopathy. Circulation 2014 0.76
22 The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol 2011 0.75
23 Finding the right academic job. Hematology Am Soc Hematol Educ Program 2009 0.75
24 Scleromyxedema with histology resembling granuloma annulare. Dermatol Online J 2014 0.75